NCT05515029
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
StatusUnknown
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2023); last known: Active, Not Recruiting
- Notable Primary completion date: Aug 15, 2025 to Aug 15, 2024
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 50 to confirmed 56
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Estimate the probability of developing acute GVHD stage II-IV after HSCT
Timeframe: evaluation period is 120 days after HSCT
severe (3-5 degrees) side effects of conditioning
Timeframe: evaluation period is 30 days after HSCT
Secondary (5)
event free survival
transplantation-associated mortality
relapse free survival
pathogen-specific immunoreconstitution
reactivation of CMV
Arms and interventions
GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab,calcineurin inhibitorExperimental
Combination products: GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
Sites
1 site in 1 country
- Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and ImmunologyMoscow, Samory-Mashela,1, Russia